Fig 1: SOST was significantly elevated in patients with cardiac remodeling after MI. (A) The mRNA expression of SOST in the serum of patients with post-MI cardiac remodeling was detected by qRT-PCR. (B) Western blot analysis was performed to assess the protein expression of SOST, with GAPDH as an internal control. (C) ELISA was conducted to detect the expression of SOST. The data are presented as mean ± SD. **P<0.01, NCRMI group vs. control group; ##P<0.01, CRMI group vs. NCRMI group. MI, myocardial infarction; SOST, sclerostin; CRMI, cardiac remodeling after MI; NCRMI, no cardiac remodeling after MI; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; qRT-PCR, quantitative real-time polymerase chain reaction; ELISA, enzyme-linked immunosorbent assay; SD, standard deviation.
Fig 2: SOST was significantly elevated in the in vivo MI model. (A) Echocardiographic measurements and histochemical staining analyses, including H&E, Masson, and Sirius Red staining, were performed to confirm the successful construction of the MI model (Bar =50 µm). Quantitative analysis of LVEDD, LVESD, LVEF, LVFS, myocyte size and fibrotic area are shown in the right panels. (B) The mRNA expression of SOST in the heart tissues was detected by qRT-PCR. (C) Western blot was used to detect the protein expression of SOST in the heart tissues, with GAPDH as the internal control. (D) ELISA was performed to detect the contents of SOST in the different groups. The data are presented as the mean ± SD (n=3). **P<0.01, model group vs. sham group. SOST, sclerostin; H&E, hematoxylin and eosin; LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic dimension; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; MI, myocardial infarction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; SD, standard deviation.
Fig 3: SOST exacerbated the postinfarct pathological myocardial remodeling in vivo. (A,B) qRT-PCR and Western blot analysis to detect the expression of SOST in the SOST-overexpression group and the sh-SOST group, respectively. GAPDH was used as the internal control. (C,D) Echocardiographic measurements and histochemical staining analyses, including H&E, Masson, Sirius Red staining and CD31+ capillaries, to assess the effects of SOST on cardiac remodeling after MI in vivo (Bar =50 µm). Quantitative analysis of LVEDD, LVESD, LVEF, LVFS, myocyte size, fibrotic area, and CD31+ capillaries are shown in the right panel. The data are presented as mean ± SD. **P<0.01, SOST-overexpression group vs. model group; ##P<0.01, sh-SOST group vs. model group. SOST, sclerostin; sh, short hairpin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; H&E, hematoxylin and eosin; LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic dimension; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; qRT-PCR, quantitative real-time polymerase chain reaction; SD, standard deviation.
Fig 4: The expression of the Wnt pathway marker proteins was affected by SOST. (A) The mRNA expression of the Wnt pathway marker genes, including Wnt1, ß-catenin, APC, and GSK3ß, was detected by qRT-PCR. (B) Western blot was used to detect the protein expression of Wnt1, ß-catenin, APC, and GSK3ß. GAPDH was used as the internal control. The data are presented as the mean ± SD (n=3). *P<0.05, SOST-overexpression group vs. control group; **P<0.01, SOST-overexpression group vs. control group; ##P<0.01, sh-SOST group vs. control group. SOST, sclerostin; sh, short hairpin; APC, adenomatous polyposis coli; GSK3ß, glycogen synthase kinase 3ß; qRT-PCR, quantitative real-time polymerase chain reaction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; SD, standard deviation.
Fig 5: The expression of Wnt signaling marker proteins was affected by SOST in vivo. (A) The expression of Wnt signaling marker genes was detected by qRT-PCR, including Wnt1, ß-catenin, APC, and GSK3ß. (B) Western blot was used to detect the protein expression of Wnt1, ß-catenin, APC, and GSK3ß. GAPDH was used as the internal control. (C) Immunofluorescence assays were performed to detect the expression of the Wnt signaling marker proteins (Bar =50 µm). Immunohistochemical staining: green fluorescence marks the corresponding protein and blue fluorescence marks the nucleus. The data are presented as the mean ± SD. *P<0.05, SOST-overexpression group vs. model group; **P<0.01, SOST-overexpression group vs. model group; ##P<0.01, sh-SOST group vs. model group. SOST, sclerostin; sh, short hairpin; APC, adenomatous polyposis coli; GSK3ß, glycogen synthase kinase 3ß; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; qRT-PCR, quantitative real-time polymerase chain reaction; SD, standard deviation.
Supplier Page from Abcam for Human SOST ELISA Kit